General Information
Revision date
2024-08-01
Product name
7582
CAS No.
78-93-3
REACH No
01-2119457290-43
Manufacturer Name
Carboline Norge AS
Emergency telephone
+1 703 5273887, +3851 2348 342
Icons in SDS
Company Information
company name
Carboline Norge AS
e-mail address of the competent person responsible for the Safety Data Sheet
hms@carboline.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H225, H319, H332, H336
Hazard statements
Code
Statements
H225
Highly Flammable liquid and vapour
Section 2
SECTION 2: Hazards identification
Hazard statements
Skin Cracking EUH066 Flam. Liq. 2 H225 Eye Irrit. 2 H319 Acute Tox. 4 Inhalation H332 STOT SE 3 NE H336 Skin Cracking EUH066 Repeated exposure may cause skin dryness or cracking. Flam. Liq. 2 H225 Highly flammable liquid and vapour. Eye Irrit. 2 H319 Causes serious eye irritation. Acute Tox. 4 Inhalation H332 Harmful if inhaled. STOT SE 3 NE H336 May cause drowsiness or dizziness.
2.2 Label elements
Symbol(s) of Product
Signal word
Danger Named Chemicals on Label butanone
Precautionary statements
P210 Keep away from heat/sparks/open flames/hot surfaces. – No smoking. P261 Avoid breathing dust/fume/gas/mist/vapours/spray. P280 Wear protective gloves/protective clothing/eye protection/ face protection. P337+313 If eye irritation persists: Get medical advice/attention. P403+235 Store in a well-ventilated place. Keep cool.
2.3 Other hazards
Vapours may form explosive mixtures with air. Solvent vapours are heavier than air and may spread along floors and ignite.
Results of PBT and vPvB assessment
The product does not meet the criteria for PBT/vPvB in accordance with Annex XIII. Endocrine disrupting properties - Toxicity Based on the available data, the product does not contain substances identified as having endocrine disrupting properties according to Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 in concentration of 0,1% or higher. Endocrine disrupting properties - Ecotoxicity Based on the available data, the product does not contain substances identified as having endocrine disrupting properties according to Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 in concentration of 0,1% or higher.
